Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Recher

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Therapeutische Umschau. Revue Therapeutique|January 8, 2014
[Primary and secondary immunodeficiencies]Nathan Cantoni, Mike Recher
Therapeutische Umschau. Revue Therapeutique|July 29, 2022
[Treatment of Patients with Immunodeficiency]Julius Christoph Köppen, Mike Recher
Rheumatology (Oxford, England)|October 3, 2017
Interleukin-6 flags infection in tocilizumab-treated giant cell arteritisChristoph T Berger, Mike Recher, Thomas Daikeler
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Immunologically induced, complement-dependent up-regulation of the prion protein in the mouse spleen: follicular dendritic cells versus capsule and trabeculaeMarius Lötscher, Mike Recher, Lukas Hunziker, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|August 28, 2010
Genes determining the course of virus persistence in the liver: lessons from murine infection with lymphocytic choriomeningitis virusPhilipp A Lang, Mike Recher, Dieter Häussinger, et al.
Current Rheumatology Reports|August 3, 2022
Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency DiseasesFabian Lötscher, Roxana Pop, Pascal Seitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2003
Public versus personal serotypes of a viral quasispeciesLukas Hunziker, Adrian Ciurea, Mike Recher, et al.
Current Opinion in Microbiology|September 11, 2004
Public, private and non-specific antibodies induced by non-cytopathic viral infectionsMike Recher, Lukas Hunziker, Adrian Ciurea, et al.
Annals of the Rheumatic Diseases|January 24, 2019
Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapsesChristoph T Berger, Birke Rebholz-Chaves, Mike Recher, et al.
Rheumatology International|January 2, 2010
Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?Mike Recher, Ulrike Sahrbacher, Juliane Bremer, et al.
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Therapeutische Umschau. Revue Therapeutique|January 8, 2014
[Primary and secondary immunodeficiencies]Nathan Cantoni, Mike Recher
Therapeutische Umschau. Revue Therapeutique|July 29, 2022
[Treatment of Patients with Immunodeficiency]Julius Christoph Köppen, Mike Recher
Rheumatology (Oxford, England)|October 3, 2017
Interleukin-6 flags infection in tocilizumab-treated giant cell arteritisChristoph T Berger, Mike Recher, Thomas Daikeler
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2003
Immunologically induced, complement-dependent up-regulation of the prion protein in the mouse spleen: follicular dendritic cells versus capsule and trabeculaeMarius Lötscher, Mike Recher, Lukas Hunziker, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|August 28, 2010
Genes determining the course of virus persistence in the liver: lessons from murine infection with lymphocytic choriomeningitis virusPhilipp A Lang, Mike Recher, Dieter Häussinger, et al.
Current Rheumatology Reports|August 3, 2022
Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency DiseasesFabian Lötscher, Roxana Pop, Pascal Seitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2003
Public versus personal serotypes of a viral quasispeciesLukas Hunziker, Adrian Ciurea, Mike Recher, et al.
Current Opinion in Microbiology|September 11, 2004
Public, private and non-specific antibodies induced by non-cytopathic viral infectionsMike Recher, Lukas Hunziker, Adrian Ciurea, et al.
Annals of the Rheumatic Diseases|January 24, 2019
Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapsesChristoph T Berger, Birke Rebholz-Chaves, Mike Recher, et al.
Rheumatology International|January 2, 2010
Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?Mike Recher, Ulrike Sahrbacher, Juliane Bremer, et al.
Pageof 13